Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strata Skin Sciences's Other Operating Expense for the
three
months ended in Dec. 2025 was €0.58 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.00 Mil.
Strata Skin Sciences's quarterly Other Operating Expense
declined
from Jun. 2025 (€-0.00 Mil) to Sep. 2025 (€-0.58 Mil) but then
increased
from Sep. 2025 (€-0.58 Mil) to Dec. 2025 (€0.58 Mil).
Strata Skin Sciences's annual Other Operating Expense
increased
from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then
declined
from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).
Strata Skin Sciences Other Operating Expense Related Terms
Strata Skin Sciences Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Skin Sciences Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €-0.00 Mil mean?
Strata Skin Sciences (FRA:E2O) has a Other Operating Expense of €-0.00 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Strata Skin Sciences and its competitors.
Is Strata Skin Sciences' Other Operating Expense too high?
Strata Skin Sciences' current Other Operating Expense is €-0.00 Mil. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' Other Operating Expense compare to ABT and SYK?
Strata Skin Sciences' Other Operating Expense of €-0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Strata Skin Sciences and its competitors. Strata Skin Sciences's current Other Operating Expense is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current Other Operating Expense of €-0.00 Mil. The stock's GF Value™ is €1,380.95, compared to a current price of €3.76 — trading 99.7% below its estimated fair value. The current Other Operating Expense is €-0.00 Mil. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current Other Operating Expense is €-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 99.7% below its estimated GF Value™ of €1,380.95.
Key valuation signals for FRA:E2O:
Other Operating Expense: €-0.00 Mil
GF Value™: €1,380.95 vs. price of €3.76 (99.7% below fair value)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
